Bradley A. McGregor

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.646Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes

ESMO Open(2025)10.1016/j.esmoop.2024.104105

Top 42%

0.448DataRank

Top 42%11 citations

G. G. Birch, Alia Meliki, V Moritz, Mausumi Bharadwaj, Nicholas R. Schindler +20 more

Papers

Driven by 22 papers — median percentile 46. Top paper: “Progressive immune dysfunction with advancing disease stage in renal cell carcinoma”.

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

Cancer Cell(2021)10.1016/j.ccell.2021.02.013

N/A

9.5DataRank · unranked

526 citations

Kelly Street, Kelly P. Burke, David L. Cookmeyer, Thomas Denize, Christina B. Pedersen +30 more

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies

Cancer(2020)10.1002/cncr.33328

N/A

3.1DataRank · unranked

113 citations

Matthew T. Campbell, Wanling Xie, Subrina Farah, Mehmet Asım Bilen, Andrew Schmidt +11 more

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Cancer Cell(2021)10.1016/j.ccell.2021.02.015

N/A

0.964DataRank · unranked

617 citations

Meng Xiao He, Ziad Bakouny, Abhay Kanodia, Sara Napolitano, Jingyi Wu +26 more

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

Nature Communications(2021)10.1038/s41467-021-21068-9

N/A

0.770DataRank · unranked

169 citations

David A. Braun, Sachet A. Shukla, Wenting Pan, Xīn Gào, Yue Hou +48 more

Integrative clinical and molecular characterization of translocation renal cell carcinoma

Cell Reports(2022)10.1016/j.celrep.2021.110190

N/A

0.717DataRank · unranked

118 citations

Ananthan Sadagopan, Praful Ravi, Nebiyou Y. Metaferia, Jiao Li, Shatha AbuHammad +35 more

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial

BMJ Oncology(2024)10.1136/bmjonc-2023-000181

N/A

0.536DataRank · unranked

8 citations

Yu‐Wei Chen, Martin H. Voss, Bradley A. McGregor, Mehmet Asım Bilen, Marc‐Oliver Grimm +9 more

Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.04.012

N/A

0.477DataRank · unranked

23 citations

Elio Adib, Nicole Weise, Catherine Curran, Tyler F. Stewart, Dory Freeman +9 more

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes

ESMO Open(2025)10.1016/j.esmoop.2024.104105

Top 42%

0.448DataRank

Top 42%11 citations

G. G. Birch, Alia Meliki, V Moritz, Mausumi Bharadwaj, Nicholas R. Schindler +20 more

IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer

Endocrine Related Cancer(2023)10.1530/erc-23-0241

N/A

0.345DataRank · unranked

9 citations

Victoria Wang, Raina N. Fichorova, Bradley A. McGregor, Xiao X. Wei, Shehzad Basaria +2 more

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Cancer Cell(2025)10.1016/j.ccell.2025.05.009

N/A

0.330DataRank · unranked

8 citations

Meng Xiao He, Ziad Bakouny, Abhay Kanodia, Sara Napolitano, Jingyi Wu +25 more

Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer

European Urology Oncology(2025)10.1016/j.euo.2024.10.014

N/A

0.306DataRank · unranked

3 citations

Caiwei Zhong, Wanling Xie, Emma Kelly, Bridget Whelpley, Katelyn Kuczmarski +13 more

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.28.121806

N/A

0.208DataRank · unranked

3 citations

David A. Braun, Sachet A. Shukla, Wenting Pan, Xīn Gào, Yue Hou +47 more

Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e16521

Top 65%

0.198DataRank

Top 65%2 citations

Maheetha Bharadwaj, Grace Birch, Nicholas Schindler, Chris Labaki, Renée Maria Saliby +13 more

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

Cancer Cell(2024)10.1016/j.ccell.2024.03.002

N/A

0DataRank · unranked

46 citations

Chris Labaki, Tejas Jammihal, Wanling Xie, Maxine Sun, Valisha Shah +19 more

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Cancer Immunology Research(2024)10.1158/2326-6066.cir-22-0306

N/A

0DataRank · unranked

36 citations

Lucia Kwak, Alexander Cheung, Kathryn M. Allaire, Jaqueline Marquez, David D. Yang +21 more

Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review

Cancer Treatment Reviews(2021)10.1016/j.ctrv.2021.102333

N/A

0DataRank · unranked

48 citations

Amir Mortazavi, Lisa M. Cordes, Cristina Salabao, Susan Vandlik, Andrea B. Apolo +1 more

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.10.022

N/A

0DataRank · unranked

5 citations

Salvatore La Rosa, Tian Zhang, Phillip M. Pierorazio, Laurence Albigès, Kathryn E. Beckermann +19 more

Clinical Outcomes of Patients with Oligometastatic Renal Cell Cancer Treated with Stereotactic Body Radiation Therapy: Results from a Prospective Registry Trial

International Journal of Radiation Oncology*Biology*Physics(2024)10.1016/j.ijrobp.2024.07.557

N/A

0DataRank · unranked

1 citations

Yu‐Hui Chen, Pat Doyle, H. Kang, Maeve Dillon-Martin, Theodore J. Perkins +8 more

Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.145

N/A

0DataRank · unranked

0 citations

Victoria Wang, Ole‐Petter R. Hamnvik, Yee Ming Cheung, Xiao X. Wei, Praful Ravi +3 more

Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer

JACC CardioOncology(2020)10.1016/j.jaccao.2020.08.011

N/A

0DataRank · unranked

32 citations

David Payne, Jesse Caron, Camden Bay, Bradley A. McGregor, Jon Hainer +6 more

NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4604

N/A

0DataRank · unranked

21 citations

Theodore Karrison, Bradley A. McGregor, Pedro C. Barata, Himanshu Nagar, Chad Tang +10 more

Bradley A. McGregor

Indexed papers

Top data-sharing exemplar

Papers